WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Inhibikase Therapeutics revenue was $0.00 for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $0.0, down N/A from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IKT annual revenue was $0.0, with -100% growth year-over-year.

IKT past revenue growth

How has IKT's revenue growth performed historically?

Company
-100%
Industry
497.69%
Market
20.68%
IKT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IKT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IKT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IKT revenue history

Current Revenue
$0.0
Current Earnings
-$27.5M
Current Profit Margin
0%

Be the first to know when IKT announces revenue.

IKT Revenue History By Year

IKT Yearly RevenueIKT RevenueIKT ChangeIKT Revenue Growth
2024-12-31$0.00-$260.50k-100.00%
2023-12-31$260.50k$137.06k+111.03%
2022-12-31$123.44k-$2.98M-96.02%
2021-12-31$3.10M$2.40M+343.92%
2020-12-31$698.47k-$424.27k-37.79%
2019-12-31$1.12M-$2.92M-72.22%
2018-12-31$4.04MN/AN/A

1 of 1

Inhibikase Therapeutics Revenue FAQ

What was IKT's revenue last quarter?

On Invalid Date, Inhibikase Therapeutics (NASDAQ: IKT) reported Q4 2024 revenue of $0.00 up 100% year over year. In the same quarter last year, Inhibikase Therapeutics's revenue was $1.00.

What was Inhibikase Therapeutics's revenue in 2024?

Inhibikase Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a 100% decrease year over year.

How much does Inhibikase Therapeutics make in a day?

Based on Inhibikase Therapeutics annual revenue for the past five years, IKT makes an average of $2,292.06 per day.

What was Inhibikase Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Inhibikase Therapeutics's revenue has grown -100% year over year. This is 597.69 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Inhibikase Therapeutics's revenue in the past year totaled $0.00.

How much does Inhibikase Therapeutics make in a year?

Inhibikase Therapeutics's revenue by year for the past five years is:
  • Inhibikase Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0.00, a 100% decrease year over year.
  • Inhibikase Therapeutics's annual revenue for Dec 31, 2023 was $260.50 thousand, a 111.03% increase from 2022.
  • Inhibikase Therapeutics's annual revenue for 2022 was $123.44 thousand, a 96.02% decrease from 2021.
  • Inhibikase Therapeutics's annual revenue for 2021 was $3.10 million, a 343.92% increase from 2020.
  • Inhibikase Therapeutics's annual revenue for 2020 was $698.47 thousand, a 37.79% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.